Before the market opens on 2026/4/3, overall it looks like a recovery today; only focus on innovative drugs and power grid equipment.

At this stage, the rise in oil prices can only become a tool for quantitative arbitrage; however, if oil prices dip slightly, the related energy-and-chemical sectors will just play out a limit-down move; this direction is at the poison level [Taoguba].
For more than a month, this kind of true-and-false poison has been released time and again; it has harmed people greatly;

The day before yesterday, signals of easing were released. The world surged; expectations were that tech would then get a rebound; originally, global funds expected that on Thursday morning Trump would release easing signals.
Who would have thought that yesterday, yesterday Trump dropped a major bomb; global tech plunged; oil prices surged; yesterday’s global selloff was panic that was beyond expectations;

But judging from the V-shaped performance in U.S. stocks last night, and also combining the selloff that was beyond expectations yesterday and caused panic, today most likely we will see a rebound expectation.

If there is a rebound today, treat it only as a rebound. Recently, there has never been a convincing increase in volume; overall it’s been steadily shrinking in volume. Add to that the flood of uncertain messages during the three-day holiday—expectations are everywhere.
A rebound today is a point to trim positions; at the same time, it’s also a turning point for short-term funds to rotate their holdings. Today is also a milestone for innovative drugs—whether there’s a chance for it to become the April main theme depends heavily on how it performs today.

On the board, only innovative drugs are strongest, with the sector continuously seeing high-to-low rotation.
Innovative drugs saw a North Stock Exchange 30cm-listed target for the first time yesterday, which shows that capital is doing digging in every direction. At the same time, after Minovo Pharma—previously a core holding—adjusted for two days, it surged with high volume yesterday.
Across all directions, the core positions also only have Minovo Pharma that can take a beating; today it also has a chance to make a new high. For a sector to strengthen, opportunity and pressure coexist; so innovative drugs is a node today;

The pressure is that Tianjin Pharmaceutical today is facing the need to break through a 6-board cap. Meanwhile, if Wanbangde rises another 5%+, it will face a limit-up anomaly restriction. At the same time, Uncle Sam has also released a 100% tariff negative for innovative drugs and APIs.

So today the key is to watch how innovative drugs performs;

The core is to see whether Minovo Pharma can go to a new high. No matter whether it hits limit-up and whether it reverses from there, it must make a new high.
Wanbangde has a two-day window to control anomaly changes. Will it build strength by way of high-volatility washout and then strong sideways consolidation to get through these two days? Or will it directly go to limit-up and reverse to challenge regulation by top-pinning that anomaly?
Or will it simply continue to weaken while staying underwater?
Tianjin Pharmaceutical: after a big divergence, will it break through the 6-board cap, or will it break the board but still have support? Or will it directly break the board and then weaken?

Look together at the strength of innovative drugs. If the strength matches expectations, then the low-position Double-Lu Pharmaceutical and Yibai Pharmaceutical become the node-level cost-performance core.

If innovative drugs weakens, then the power grid equipment names—Datongnan and Tongda Co.—will become what market funds focus on; and no matter how innovative drugs performs today, Datongnan will still be the market’s focal point.

Also, on the battery front, Rongjie Co. had an anomaly yesterday but didn’t hit limit-up; the whole sector is in a rebound structure, so it doesn’t amount to much.

Commercial aerospace: the rebound has been very strong lately, but it’s all rebounds by previously established veterans, with no new stocks emerging to lead strength—so it’s just a rebound, and at this position there’s no particular value in paying attention.

Also pay attention to Far Sheng and Xinghui New Materials, which are facing anomaly constraints, to observe the strength of market short-term capital.

On the computing power direction, walk with it and watch, and see whether there’s strength ahead. In short, as long as the situation in the Middle East hasn’t stabilized, technology funds will definitely be very stealthy.